Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report)'s stock price reached a new 52-week low on Wednesday . The stock traded as low as $25.81 and last traded at $25.99, with a volume of 458568 shares trading hands. The stock had previously closed at $26.95.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on VERA. Wolfe Research began coverage on Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price target for the company. Guggenheim increased their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. JPMorgan Chase & Co. lowered their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research report on Tuesday, March 4th. Finally, The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They set a "buy" rating and a $58.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Vera Therapeutics has a consensus rating of "Buy" and an average target price of $64.67.
Check Out Our Latest Analysis on Vera Therapeutics
Vera Therapeutics Price Performance
The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The company has a 50 day moving average of $30.93 and a 200-day moving average of $38.87. The stock has a market capitalization of $1.70 billion, a P/E ratio of -10.20 and a beta of 1.17.
Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.11. Sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.
Insider Transactions at Vera Therapeutics
In other news, CEO Marshall Fordyce sold 17,500 shares of the company's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the transaction, the chief executive officer now owns 143,603 shares in the company, valued at approximately $5,993,989.22. This represents a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 21.70% of the company's stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Intech Investment Management LLC bought a new stake in shares of Vera Therapeutics during the third quarter valued at approximately $475,000. Charles Schwab Investment Management Inc. raised its stake in Vera Therapeutics by 3.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,805 shares of the company's stock valued at $15,992,000 after acquiring an additional 10,717 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Vera Therapeutics by 11.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,574 shares of the company's stock worth $2,722,000 after acquiring an additional 6,494 shares during the period. Verition Fund Management LLC bought a new position in shares of Vera Therapeutics in the third quarter worth $1,910,000. Finally, Point72 Asia Singapore Pte. Ltd. increased its holdings in shares of Vera Therapeutics by 109.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 9,407 shares of the company's stock valued at $416,000 after purchasing an additional 4,914 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.
Vera Therapeutics Company Profile
(
Get Free Report)
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Read More
Before you consider Vera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.
While Vera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
